EPCAM and colorectal carcinoma: Although there is no previous report showing the immunomodulatory function of regorafenib, in this study, we constructed a second-generation CAR against EpCAM and sought to investigate whether combination therapy with the CAR-NK cells and regorafenib can enhance anticancer activity against human CRC in a mouse model.